Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology - 2Civil rights leader Jesse Jackson hospitalized, family requests prayers
- 3The Way to Business: Startup Illustrations Learned
- 4China bans storing cremated remains in empty 'bone ash apartments'
- 5The Specialty of Cleaning up: Change Your Space and Brain
- New ‘Cloud-9’ object could reveal the secrets of dark matter
- Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients
- All that You Really want to Be aware of Dental Inserts Facilities
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Four Dead in Last Month From Animal Attacks in Nepal
- Poll: Most are satisfied with their health insurance, but a quarter report denials or delays
- Brazil's ex-president Bolsonaro operated on for hernia
- Tech Patterns 2023: 12 Advancements to Keep an eye Out For
